Twist Bioscience Posts 13th Straight Growth, Sees 28% DNA and 55% Therapeutics Gains
Twist Bioscience delivered its 13th straight quarter of sequential revenue growth, led by 28% expansion in DNA Synthesis and Protein Solutions from AI-driven drug discovery investments. Therapeutics revenue surged 55%, while NGS uptake in MRD oncology diagnostics reaccelerated through faster panel customization and heightened sensitivity.
1. Sequential Revenue Growth
Twist achieved its 13th consecutive quarter of sequential revenue growth by leveraging a semiconductor-based DNA synthesis platform that reduces cost and accelerates new product introductions at scale.
2. DNA Synthesis and Protein Solutions Performance
Revenue in the DNA Synthesis and Protein Solutions segment climbed 28%, driven by early AI-enabled drug discovery partnerships that expanded from initial pilots to dozens of active customers, underpinning sustained demand.
3. Therapeutics and NGS Business Acceleration
The Therapeutics segment rose 55% as the platform served customer needs from pooled sequence libraries to end-to-end characterization, and NGS business reaccelerated through higher adoption in oncology diagnostics requiring sensitive, customizable MRD testing panels.